Protocol Ledger

NCT05671835 · Phase II · COMPLETED

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Interventional Phase II clinical trial protocol NCT05671835 sponsored by Tvardi Therapeutics, Incorporated in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-15 Enrollment: 100 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05671835
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05671835
Protocol FieldVerified Registry Value
NCT IdentifierNCT05671835
Consolidated Lead SponsorTvardi Therapeutics, Incorporated
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment100 participants (ACTUAL)
Registered Start Date2023-05-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI